AB0296 PASSIVE TRANSFER OF ANTI-SSA, ANTI-Ro52, AND ANTI-MITOCHONDRIAL M2 FROM INTRAVENOUS IMMUNOGLOBULIN PRODUCTS TO PATIENTS WITH RHEUMATIC DISEASES

Background: Passive transfer of ANA and anti-SSA has been reported in patients with common variable immunodeficiency disorder who received intravenous immunoglobulin (IVIG). IVIG is also recommended to treat some special or life-threatening rheumatic diseases. Objectives: This study was aimed explore whether any extractable nuclear antibodies (ENAs) were transferred these therapy. Methods: products three batches tested for by using indirect immunofluorescent assay, ENAs line immunoassay (LIA) chemiluminescence (CLIA). These administrated at a dose 20g/d×3 days (day1 day3). Serum samples before (day0) after (day4, day8, day10, day12, more than one month) LIA CLIA. Anti-SSA detected ELISA. Results: In products, positive titer 1:640 (cytoplasmic speckled) 1:80 (speckled). Among 14 types that could be LIA, anti-SSA, anti-Ro52, anti-mitochondrial M2, anti-centromere B clearly detectable (Table 1). Likewise, another assay CLIA the same autoantibodies products. showed highest concentration while M2 anti-Ro52. One 31-year-old male patient diagnosed as SLE (Figure 1) 72-year-old necrotizing myositis Anti-SSA, but not B, day4 serum samples, although all negative baseline (day0). The decreased gradually passed became undetectable around month IVIG. Table 1. anti-Ro-52 Cut-off LIA(grey value) 20±3 28±3 69±10 19±4 ≥11 (U/ml) 333±107 444±86 434±66 390±89 >20 ELISA 90±13 NA immunoassay; CLIA, ELISA, enzyme linked immunosorbent Conclusion: preliminarily transient positivity maybe because passive from patients, potential influence this on diseases remained unknown. Figure receiving day51) horizontal red lines corresponding cut-off values each assay. Disclosure Interests: None declared